Inflammation as a therapeutic target: A unique role for abciximab

Vascular inflammation is a central pathogenic mechanism for both acute coronary syndromes and the vascular response to injury after percutaneous coronary intervention. The magnitude of vascular inflammation has been correlated with adverse late clinical outcomes (death, myocardial infarction, recurrent ischemia, restenosis). Vascular inflammation is also increased in patients with diabetes mellitus. Many adjunctive pharmacotherapies used in the treatment of acute coronary syndromes or during percutaneous coronary intervention. have anti-inflammatory effects, which are distinct from their perceived primary mechanism of action. Data in support of the anti-inflammatory effects of abciximab are presented and the role that these effects may play in modulating atherosclerotic plaque stability and late clinical outcomes is discussed. Vascular inflammation represents the "final common pathway" for many disease processes and thus represents the "ultimate therapeutic target" for pharmacologic intervention.